Interferon News and Research

RSS

New treatment regimen for hepatitis C in transplant patients produces promising results

A new treatment regimen for hepatitis C, the most common cause of liver cancer and transplantation, has produced results that will transform treatment protocols for transplant patients, according to research published online today in the New England Journal of Medicine.

12 Nov 2014

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.

11 Nov 2014

UCSD researchers describe surprising role of protein in embryonic development

Hematopoietic stem cells (HSCs) give rise to all blood and immune cells throughout the life of vertebrate organisms, from zebrafish to humans. But details of their genesis remain elusive, hindering efforts to develop induced pluripotent stem cell (iPSC) replacements that might address a host of blood disorders.

7 Nov 2014

Insufficient Th1 polarisation blocks RCC vaccine efficacy

A lack of a clinical response to an allogenic gene-modified renal cell cancer vaccine may be due to insufficient type 1 T-helper cell polarisation, show results of a gene expression profiling study.

30 Oct 2014

YEDA and XL-protein sign deal to commercialize PASylated IFN superagonis

YEDA Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist -- PAS-YNSα8 -- which has been jointly developed by scientists at the Weizmann Institute and XL-protein.

21 Oct 2014

FDA approves new hepatitis C drug, Harvoni

Insurers and patients are decrying the cost for the new drug, nearly $95,000 for a 12-week course of treatment, which is more expensive than Gilead's other hepatitis C drug, Sovaldi. But unlike some hepatitis C treatments, Harvoni can be taken without injections usually given to hepatitis C patients.

14 Oct 2014

RPS Diagnostics receives CE mark for FebriDx test

RPS Diagnostics, Inc. today announced CE mark of its FebriDx test, clearing the way for sales in the European Union and all countries recognizing the CE mark.

9 Oct 2014

Finding ways to rejuvenate "immunological age" of the brain

How the brain ages is still largely an open question - in part because this organ is mostly insulated from direct contact with other systems in the body, including the blood and immune systems. In research that was recently published in Science, Weizmann Institute researchers Prof. Michal Schwartz of the Neurobiology Department and Dr. Ido Amit of Immunology Department found evidence of a unique "signature" that may be the "missing link" between cognitive decline and aging.

30 Sep 2014

SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

After the success of a new drug treatment in adults with hepatitis C infection, a Saint Louis University pediatric researcher is testing the safety and efficacy of the medications in children.

21 Sep 2014

T-bet protein fights off hepatitis infections

A single protein may tip the balance between ridding the body of a dangerous virus and enduring life-long chronic infection, according to a report appearing in The Journal of Experimental Medicine.

16 Sep 2014

Gilead to boost price of new hepatitis c drug

Gilead Sciences says its next generation drug to combat hepatitis C, slated to launch next month, will be more expensive than $1,000-a-pill Sovaldi, in part because the new treatment will be shorter and simpler. Gilead also struck a deal with Indian generic drugmakers to sell lower-cost versions of Sovaldi in poor countries.

From Baxter International Inc. 16 Sep 2014

Researchers explain why people with asthma have hard time dealing with respiratory viruses

People with asthma often have a hard time dealing with respiratory viruses such as the flu or the common cold, and researchers have struggled to explain why.

10 Sep 2014

Study compares breast and bottle fed infants

Infant rhesus monkeys receiving different diets early in life develop distinct immune systems that persist months after weaning, a study by researchers from UC Davis, the California National Primate Research Center (CNPRC) at UC Davis and UC San Francisco have shown.

5 Sep 2014

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company, has released an update on the clinical trial pipeline for its lead immunotherapy products treating basal cell carcinoma (BCC) and breast cancer.

4 Sep 2014

Scientists aim to develop rapid test system for immune dysfunction to treat cystic fibrosis

Cystic fibrosis (CF) is a frequent genetic disease affecting the lung and the gastrointestinal tract. Scientists from the Helmholtz Zentrum München now have shown that many of the adult patients with CF in addition lack a cell surface molecule, which is important for immune defence. The results have been published recently in the 'Journal of Molecular Medicine'.

4 Sep 2014

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Bristol-Myers Squibb today announced the launch of Daklinza▼ (daclatasvir) in the UK, a new medicine for the treatment of adult patients with chronic hepatitis C. Daclatasvir, a treatment that works across multiple hepatitis C genotypes, will allow up to 90% of UK patients the option of a potentially curative oral treatment regimen that does not include interferon, a standard of care commonly associated with sustained flu-like side effects.

4 Sep 2014

NASA study reveals how spaceflight affects immune system of crew members

There is nothing like a head cold to make us feel a little dazed. We get things like colds and the flu because of changes in our immune system. Researchers have a good idea what causes immune system changes on Earth-think stress, inadequate sleep and improper nutrition.

19 Aug 2014

Ebola virus defeats attempts by interferon to block viral reproduction in infected cells

One of the human body's first responses to a viral infection is to make and release signaling proteins called interferons, which amplify the immune system response to viruses.

14 Aug 2014

Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate has been approved since January 2014 for adults with relapsing remitting multiple sclerosis.

8 Aug 2014

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet.

29 Jul 2014

Interferon News and Research

New treatment regimen for hepatitis C in transplant patients produces promising results

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

UCSD researchers describe surprising role of protein in embryonic development

Insufficient Th1 polarisation blocks RCC vaccine efficacy

YEDA and XL-protein sign deal to commercialize PASylated IFN superagonis

FDA approves new hepatitis C drug, Harvoni

RPS Diagnostics receives CE mark for FebriDx test

Finding ways to rejuvenate "immunological age" of the brain

SLU pediatric researcher to study efficacy of new hepatitis C drug treatment in children

T-bet protein fights off hepatitis infections

Gilead to boost price of new hepatitis c drug

Researchers explain why people with asthma have hard time dealing with respiratory viruses

Study compares breast and bottle fed infants

Ascend Biopharmaceuticals provides update on clinical trial program for lead immunotherapy products

Scientists aim to develop rapid test system for immune dysfunction to treat cystic fibrosis

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

NASA study reveals how spaceflight affects immune system of crew members

Ebola virus defeats attempts by interferon to block viral reproduction in infected cells

Dimethyl fumarate offers no added benefits for adults with RRMS

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News